1d agoSeeking AlphaNEUTRAL 50Earnings
Liquidia Corporation 2026 Q2 - Results - Earnings Call Presentation
2026-08-12. The following slide deck was published by Liquidia Corporation in conjunction with their 2026 Q2 earnings call.
Archived explainer. For the current picture see today's LQDA page.
Why Is LIQUIDIA CORP (LQDA) Stock Down Today?
By the Top Tier Newswire AI Desk · August 13, 2026 at 12:17 AM ET · reviewed against 13 wire stories
LIQUIDIA CORP (LQDA) is down -10.52% in the latest session. Our newswire has captured 13 stories on LQDA across 9 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why LQDA stock is down today
Liquidia Corp (LQDA) fell 10.52% to $78.79 in the session, driven by a combination of a revenue beat and an earnings miss in its Q2 2026 report. The company reported net product sales of $170.4 million, a significant increase from $6.5 million in the same period last year, primarily due to higher YUTREPIA sales. However, the earnings per share of $0.74 fell short of the expected $0.41, contributing to the stock's decline.
What Happened
Liquidia’s Q2 earnings call highlighted strong sales growth for its inhaled treprostinil product, YUTREPIA, with the company capturing approximately 30% of the inhaled prostacyclin market. CEO Roger Jeffs noted the growing demand for the drug, which treats lung disease. Despite the revenue beat, the company missed earnings estimates, which led to a negative market reaction. The earnings call also outlined an expanding investment in the clinical pipeline, including a 327-case study.
The stock's drop followed the release of the earnings report and the subsequent analysis by analysts and investors. While Needham and BTIG maintained Buy ratings and raised price targets to $110 and $111 respectively, LifeSci Capital downgraded the stock to Market Perform with a $90 price target. The mixed analyst sentiment, combined with the earnings miss, contributed to the sharp decline in LQDA shares.
What The Data Shows
The stock traded at a P/E ratio of 379.3, with a market cap of $8.0B and a beta of 0.57. Over the past year, LQDA has traded between $19.90 and $93.61. The company reported a 1936.7% year-to-date revenue increase and a net margin of 7.7%. Notably, insider selling activity has been significant, with 30 sales totaling $140.6 million reported in the last 90 days. The most recent insider transactions occurred on July 27 and July 29, involving key executives and directors.
What To Watch
The stock is currently without scheduled earnings in the near term. Investors should monitor the breadth of analyst coverage and any further developments in the company’s clinical pipeline or regulatory landscape.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
LQDA by the numbers
Last: $78.79Session: -10.52%Coverage: 13 stories / 9 sourcesAI sentiment: 56/100 (mixed)Mkt cap: $8.0BP/E: 379.352w: $19.90 to $93.61
The headlines behind the move
1d agoSeeking AlphaBULLISH 73Earnings
Liquidia targets more than $1B in 2027 net revenue as YUTREPIA nears 30% of inhaled prostacyclin market
Liquidia (LQDA) Q2 2026 earnings call: YUTREPIA sales surge, ~30% inhaled market share, $1B+ 2027 goal, R&D ramp and 327 case—read now.
1d agoSeeking AlphaNEUTRAL 50Earnings
Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript
Liquidia Corporation (LQDA) Q2 2026 Earnings Call August 12, 2026 8:30 AM EDTCompany ParticipantsJason Adair - Chief Business OfficerRoger Jeffs - CEO &...
1d agoInvestors.comBEARISH 38Earnings
Why No. 2 IBD 50 Stock, Liquidia, Dropped Despite Its Sales Beat
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
1d agoYahoo FinanceBULLISH 63Earnings
Liquidia Q2 Earnings Call Highlights
Liquidia (NASDAQ:LQDA) reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical pipeline. Chief Executive Officer Roger Jeffs said the company had received approximately 5,900 uniq
1d agoStocktwits NewsBULLISH 69Earnings
Liquidia CEO Roger Jeffs Says Demand For Inhaled Lung Disease Drug Is Growing Amid Q2 Revenue Beat
Net product sales for the second quarter surged to $170.4 million from $6.5 million last year, due to higher Yutrepia sales volumes.
1d agoInvestors.comBULLISH 69Earnings
Liquidia, An IBD 50 Stock, Tops Sales Views Amid United Therapeutics Rivalry
Liquidia topped second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits.
1d agoInvestorsHubBEARISH 38Earnings
Liquidia shares fall after second-quarter earnings miss despite revenue growth
Liquidia shares fall after Q2 earnings miss estimates, despite strong revenue growth driven by $170.4 million in YUTREPIA sales and rising patient adoption.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on LQDA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier LQDA move explainers: 2026-08-13 · 2026-08-12 · 2026-07-14